A regulatory circuit between NK cells and ILC2s is supported by three lines of evidence: NK cell recovery occurring after IL-4 blockade; ILC2 accumulation in AD lesions of NK cell-deficient mice; and NK cell recovery and activation after IL-15 superagonist treatment leading to reduced ILC2 levels and disease scores in an AD model (152). Here, IL15 is linked to Alzheimer disease.